SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- MicroIslet Inc. (Amex: MII)
announced that its President and COO Haro Hartounian, Ph.D. will speak at the
Rodman & Renshaw 7th Annual Techvest Healthcare Conference on Tuesday,
November 8th at 3:30 PM (EST) in the Holmes II Room at the New York Palace
Hotel in New York City. MicroIslet is one of over 290 invited companies to
present at this conference, to be held November 7-9, 2005.
MicroIslet is not only seeking to free millions of insulin-dependent
diabetics from daily injections in the near term, but potentially to offer
them a curative treatment in the long term. In his presentation at the
conference, Dr. Hartounian will present the Company's innovative strategy for
using microencapsulated porcine islets to treat insulin-dependent diabetes and
its potential to reduce the staggering $132 billion that the CDC estimates is
spent each year on diabetes-related healthcare. Highlights will include the
Company's stellar roster of Scientific Advisory Board members, its strategic
partnerships, including a unique islet supply partnership with the Mayo
Clinic, and the potential impact of the recently enacted Pancreatic Islet Cell
A live webcast of the presentation can be accessed by following the link
for MicroIslet on the "Conference Webcasting" page under "Upcoming
Conferences" at www.rodmanandrenshaw.com, URL
http://wsw.com/webcast/rrshq7/mii/, or through the investor relations section
of the Company's website at www.microislet.com. Listeners are encouraged to
visit the Web site at least 15 minutes prior to the beginning of the scheduled
presentation to register and download and install any necessary audio
software. The presentation will be archived on the same Web sites and
available for a 90-day period.
MicroIslet is a biotechnology company engaged in the research,
development, and commercialization of patented technologies in the field of
transplantation therapy for people with insulin-dependent diabetes.
MicroIslet's patented islet transplantation technology, exclusively licensed
from Duke University, includes methods for isolating, culturing,
cryopreservation, and immuno-protection (microencapsulation) of islet cells.
MicroIslet is working to develop and commercialize a first product, called
MicroIslet-P(TM), a microencapsulated porcine islet cell suspension that will
be used for transplantation in patients with insulin-dependent diabetes.
Except for the historical information contained herein, the matters set
forth in this press release, including the anticipated benefits of data from
The Scripps Research Institute in guiding primate studies of MicroIslet's
microencapsulated porcine islet cell suspension, the expectation of
development of new therapeutic products, and the impact of MicroIslet's
products on diabetes patients, are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
the risks and uncertainties inherent in medical treatment discovery,
development and commercialization, the risks and uncertainties associated with
MicroIslet's early stage xenotransplantation technologies, the risks and
uncertainties of governmental approvals and regulation, MicroIslet's need to
raise substantial additional capital to execute its business plan, the risks
that MicroIslet's competitors will develop or market technologies or products
that are more effective or commercially attractive than MicroIslet's products,
and other risks detailed from time to time in MicroIslet's most recent filings
with the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. MicroIslet disclaims any intent or
obligation to update these forward-looking statements.
For more information, please visit our Web site at www.microislet.com.
For further information, please contact: Haro Hartounian, Ph.D., President
and Chief Operating Officer of MicroIslet, Inc., +1-858-657-0287,
SOURCE MicroIslet Inc.
/CONTACT: Haro Hartounian, Ph.D., President and Chief Operating Officer
of MicroIslet, Inc., +1-858-657-0287, email@example.com/
/Web site: http://wsw.com/webcast/rrshq7/mii /
/Web site: http://www.rodmanandrenshaw.com /
/Web site: http://www.microislet.com /
CO: MicroIslet Inc.
ST: California, New York
IN: HEA MTC BIO
SU: TDS CCA
-- LATH036 --
5670 11/03/2005 08:00 EST http://www.prnewswire.com